Collaboration lies at the core of our business at Martin Dow Marker Ltd.
We are built on the foundation of care, collaboration, and continual development that enables us to push the boundaries of life-improving medicines.
We seek to build valuable business partnerships based on the ideals of transparency, shared success, and trust. Together with our partners, we aim to brighten the horizon for countless lives benefitting from our high-quality products.
Martin Dow Ltd. builds robust partnerships with leading pharmaceutical companies across the globe.
We offer our partners a wide range of partnership opportunities, varying from mergers & acquisitions to licensing & distribution models.
We have a hybrid business growth model with our generic product portfolio through strategic partnerships with global industry leaders.
We partner with peer companies and biotech to enhance our portfolio and pipeline within our main therapy areas which include manufacturing, marketing, selling, and distribution of their leading brands.
Merck kGaA, Sanofi, and products for in-licensing.
Nutraceuticals from third-party manufacturers.
We maximize value through effective, and long-term partnerships such as by acquiring technical facilities, leading brands, and licensing rights of key brands.
Merck KGaA (2016) business acquisitions in Pakistan.
We focus on the development of key assets within our core therapy areas.
This is accomplished through accessing external therapy area expertise.
Contract manufacturing through local partners for Nutraceutical, health and OTC products
We successfully provide our partners with access to technologies and reach into emerging markets of South Asia, Southeast Asia, Central Asia and East Africa.